Corvus Pharmaceuticals, Inc.
CRVSCorvus Pharmaceuticals, Inc. is a pharmaceutical company focused on developing targeted therapies for cancer and immuno-oncology. Founded in 2014 and based in Burlingame, California, the company concentrates on designing small molecule drugs intended to modulate the immune system to improve cancer treatment outcomes.
Company News
Corvus Pharmaceuticals priced an upsized underwritten public offering of 7.9 million shares at $22.15 per share, raising approximately $175 million in gross proceeds. The company plans to use the funds for working capital, R&D including Phase 3 T cell lymphoma and Phase 2 atopic dermatitis trials, and general corporate purposes. The offering is e...
Corvus Pharmaceuticals presented interim data from a Phase 1b/2 clinical trial of ciforadenant for metastatic renal cell cancer, showing promising results when combined with ipilimumab and nivolumab, with a 34% deep response rate and favorable safety profile.
Over 20 pharmaceutical companies are actively developing Interleukin-2 (IL-2) inhibitors to address autoimmune diseases and organ transplant procedures, with promising pipeline drugs in various clinical trial stages.
U.S. stock futures climbed on Wednesday as investors await the Federal Reserve's interest rate decision and economic data releases. The Dow Jones index extended its losing streak to nine consecutive sessions, the longest since 1978.
Corvus Pharmaceuticals presented new preclinical data showing that their lead ITK inhibitor, soquelitinib, can prevent lung damage, inflammation, and pulmonary hypertension in mouse models of systemic sclerosis, an autoimmune disease. The data supports the potential of ITK inhibition as a novel therapeutic approach for immune-mediated fibrotic di...
